Mathias Hornef, MD

RWTH Aachen
Aachen Germany
Biographical Sketch: Mathias studied medicine in Tübingen, Lübeck, New York and Lausanne. He was then trained in Medical Microbiology at the Max von Pettenkofer Institute in Munich before he joined the group of Staffan Normark at the Karolinska Institute in Stockholm for a postdoctoral period. He later became Assistent Professor at the Swedish Center for Infectious Diseases with a stipend of the Swedish Research Council. Mathias then moved first as an independent PI to the Ludwig Albert University Freiburg and then as a Professor of Molecular Medical Microbiology to Hannover Medical School. Since 2014 he heads the Institute of Medical Microbiology of the RWTH University Clinic in Aachen.

Any personal financial relationships? No

I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.

The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.

I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.

I agree to provide educational content and resources in advance for review if requested by ICMI.

If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.

If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.

1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.

2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).

3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.

4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".

Signed on 02/09/2015 by Mathias W. Hornef

Papers:
Ontogeny of the Enteric Mucosal Immune System and the Host's Susceptibility to Infection
F.31 Active suppression of intestinal CD4⁺TCRαβ⁺ T lymphocyte maturation during the postnatal period
F.63 ORAL ENTEROPATHOGENIC E. coli (EPEC) INFECTION of NEWBORN MICE
T.118 Dedicated Immunosensing of Mouse Intestinal Epithelium Facilitated by Genetically Coupled Lectin-like Receptors

	I have disclosed to ICMI all relevant financial relationships, and hereby allow ICMI to disclose this information to learners in print.
	The content and/or presentation of the information with which I am involved, including any presentation of therapeutic options, will be well-balanced, evidence-based, and will not promote specific proprietary business interests of a commercial interest. Any product identification will be made using the generic names to the extent possible. In addition, any off-label use of a medication will be specifically disclosed.
	I have not and will not accept any additional honoraria, payments or reimbursements beyond that which has been agreed upon directly with ICMI.
	I agree to provide educational content and resources in advance for review if requested by ICMI.
	If I have been trained or utilized by a commercial entity or its agent as a speaker (e.g., speaker’s bureau) for any commercial interest, the promotional aspects of that presentation will not be included in any way with this activity.
	If I am presenting research funded by a commercial company, the information presented will be based on generally accepted scientific principles and methods, and will not promote the commercial interest of the funding company.
	1. I will insure balance, independence, objectivity, and scientific rigor in my role in the planning, development or presentation of this CME activity.
	2. I will comply with the requirements to protect health information under the Health Insurance Portability & Accountability Act of 1996 (HIPAA).
	3. I will disclose any discussion or reference to unapproved or unlabeled uses of therapeutic agents or products.
	4. I have input my full name below as attestation of agreement with declaration statements. Marking the check box and indicating my name is in lieu of signature and is considered an "e-signature".